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ABSTRACT  Preincubation of Swiss 3T3 cells or human fibroblasts with purified platelet-derived 
growth  factor  (PDGF) at 4°C or 37°C  rapidly  inhibits subsequent  binding of  12~l-epidermal 
growth factor (12SI-EGF). The effect does not result from competition  by PDGF for binding to 
the EGF receptor since  (a)  very low concentrations of PDGF are effective, (b)  cells with EGF 
receptors  but no PDGF receptors  are  not affected, and  (c)  the inhibition persists even  if the 
bound  PDGF is eluted  before  incubating the ~:ells with ~2~I-EGF. PDGF does  not affect  12Sl- 
insulin  binding  nor does  EGF affect  12~I-PDGF binding  under  these  conditions.  Endothelial 
cell-derived  growth factor also competes for binding to PDGF receptors  and  inhibits t251-EGF 
binding. The inhibition demonstrated  by PDGF seems to result from  an increase in the  Kn for 
~251-EGF binding with no change  in the number of EGF receptors. 
A  number of substances have been shown to affect L25I-EGF 
binding to cells after a  period of preincubation at 37°C,  in- 
eluding dexamethasone  (1),  fibroblast-derived growth  factor 
(2),  vasopressin (3),  and lipid-interacting substances (4).  Lee 
and  Weinstein (5) found  that  different phorbol esters could 
inhibit  L25I-EGF  binding  in  proportion  to  their  potency  as 
tumor promoters. The effect is temperature-dependent (3, 6, 7, 
8) and seems to reflect a  decrease in the affmity of the EGF 
receptor (3),  possibly by eliminating a  high affinity class of 
EGF receptors (8). Phorbol acetate does not seem to affect L25I- 
insulin binding (7). Phorbol esters seem to have specific binding 
sites on responsive ceils (9, 10), so it is possible that their effect 
on EGF binding is mediated through a specific receptor. 
Recently, incubation with PDGF at 37°C has been shown 
to decrease the binding of t2~I-EGF (11, 12,  13), reportedly by 
reducing the number of EGF receptors (11,  13). PDGF is the 
major mitogen  in serum  for many connective tissue cells in 
culture (14,  15,  16). At 37°C cells respond rapidly to PDGF 
with changes in several processes that  could have secondary 
effects on receptors for EGF and other growth factors. PDGF 
stimulates the phosphorylation of cytoplasmic proteins on ty- 
rosine within  1 min (17), increases phosphatidylinositol turn- 
over within 2  min  (18),  phosphorylation of a  33-dalton cell 
protein within 3 min (19), the appearance of membrane ruffles 
and microvitli within 20 min (20), and increased amino acid 
uptake within 1 h (21).  Over a period of several hours, PDGF 
increases the number of LDL receptors (22, 23) and somato- 
medin C receptors (24).  Serum stimulates arRb+ influx within 
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2 min (26),  hexose uptake within  10 min (25),  and phospho- 
fructokinase activity within 30 min (27). This series of complex 
responses  makes  it  difficult to  distinguish direct interaction 
between  PDGF  and  EGF  receptors from  effects  which  are 
secondary to the metabolic effects of PDGF. In an attempt to 
reduce the possibilities for secondary effects of PDGF on EGF 
receptors, we have investigated the effects of PDGF and other 
hormones  on  mSI-EGF binding  in  a  system  in  which  both 
pretreatment  and  binding  determinations  are  performed  at 
4°C. 
MATERIALS AND  METHODS 
The Swiss mouse 3T3-DI  cells used in most of the studies reported here were 
cloned from Swiss 3T3 cells obtained from R. Pollack (State University of New 
York at Stony Brook). The A-431 human carcinoma ceUs were obtained from B. 
Gallis (University of Washington, Seattle). The adult human diploid foreskin 
fibroblasts (HF) were obtained essentially as described by Baker et al. (1).  The 
variant 3T3-PF2 cell was selected by [aH]thymidine suicide against mitogenic 
response to PDGF, as described in Bowen-Pope and Ross (28), and recloned for 
these experiments (now designated 3T3-PF2  (f)). Culture methods were those 
previously described (28). Binding of 12~I-ligand was initiated, as described in the 
figure and table legends, either by adding 50/xl of ~2'~l-ligand directly to the 
preincubation  medium or  by rinsing the  cultures and  incubating with fresh 
binding medium  containing  12Sl-ligand alone.  The  methods  for  determining 
specific binding were those previously described (28). Nonspecific binding of t25I- 
PDGF and I~I-EGF averaged I-3% and 5-15%, respectively, of total binding. 
PDGF was radioiodinated to a specific activity of about 40,000 cpm/ng, essen- 
tially as previously described (28).  EDGF was prepared from serum-free condi- 
tioned medium of confluent bovine aortic endothelial  cells as previously  described 
(29).  Briefly, the medium was centrifuged for 6 ×  10" g-minutes, concentrated 
30-fold by ultrafiltration (final protein concentration 655 pg/ml), and dialyzed 
679 exhaustively against 1 mM  ammonium bicarbonate.  ~l-insulin and  ~'~I-EGF 
were obtained from New England Nuclear (Boston, MA). Highly purified human 
PDGF was prepared as previously described (30). EGF and FGF were obtained 
from Collaborative Research (Waltham, MA) and porcine insulin from Sigma 
Chemical Co. (St. Louis, MO). 
RESULTS 
Reduction of  ~2~I-EGF Binding by Preincubation 
with PDGF at 4 °C 
Fig.  I a  shows the effect of incubation of 3T3 cells at 4°C 
with PDGF on subsequent binding of I~I-PDGF or ~I-EGF. 
As  expected,  E~I-PDGF binding  is reduced  by  competition 
with unlabeled PDGF for the PDGF receptor (28, 3l). Unex- 
pectedly, the  preincubation with  PDGF  also reduces  subse- 
quent 12~I-EGF binding (Fig I a), even though all incubations 
were  performed at  4°C  to  prevent  internalization of bound 
ligand (32, 33, 34) and possible cointernalization of PDGF and 
EGF  receptors.  Inhibition of ~I-EGF  binding is detectable 
with concentrations of PDGF too low to produce measurable 
competition for  I~I-PDGF  binding  under  these  conditions. 
The  maximal  effect  of PDGF  in  this  experiment  is  a  60% 
decrease  in  ]~I-EGF  binding  at  2  ng/ml  PDGF,  with  no 
further decrease occurring at higher concentrations of PDGF. 
The converse effect is not seen, i.e., preincubation with EGF 
at concentrations sufficient to saturate the EGF receptor does 
not affect r~5I-PDGF binding (Fig. I b). The small reduction in 
t"~I-PDGF binding seen in this experiment was not reproduc- 
ible. 
Mediation through PDGF Receptors 
The concentration dependence of PDGF inhibition of ~251- 
EGF  binding suggested that  the  effect is mediated through 
PDGF receptors and not through a direct effect of PDGF on 
EGF receptors. To look for direct effects we used A-431 cells, 
which have EGF receptors but not PDGF receptors (28,  31, 
35). Even extremely high concentrations of PDGF (120 ng/ml) 
do  not  reduce  ~25I-EGF  binding  to  A-431  cells  (data  not 
shown). We have also selected a variant line of 3T3 cells (3T3- 
PF2 (f)) that shows a  greatly reduced mitogenic response to 
PDGF  and  expresses only  ~5%  of the  parental number  of 
PDGF receptors per cell (28),  but that expressed the parental 
number  of EGF  receptors. Fig 2  shows that  PDGF  reduces 
~2~I-EGF binding to these ceils, but to a much smaller extent 
than it does to normal 3T3 ceils. This suggests that the inhibi- 
tion  of I~I-EGF  binding  by  PDGF  is  proportional to  the 
number of PDGF receptors present.  However, until the bio- 
chemical nature  of the defect in clone PF2(f)  is known,  we 
cannot use this cell line to make any exact calculations as to 
the relationship between occupied PDGF receptors and inhi- 
bition  of EGF  binding.  Inhibition  of ~z~I-EGF  binding  by 
PDGF is not unique to 3T3 cells since binding of ~I-EGF to 
diploid human  fibroblasts, which  express  both  PDGF  and 
EGF receptors (28, 31, 32), is also reduced by preincubation at 
4°C with PDGF (Fig. 2). 
Simultaneous  Occupation of the PDGF 
Receptors is Not Required 
In the previous experiments PDGF was present prior to, and 
during, incubation with 12~I-EGF.  To determine whether the 
inhibition of 125I-EGF binding requires continuous occupation 
of the PDGF receptors by PDGF during the period of ~25I- 
EGF binding, we removed nonbound PDGF with PBS rinses 
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FIGURE  1  Effect of preincubation with PDGF or EGF on subsequent 
'251-PDGF and  ~251-EGF binding.  Confluent  quiescent cultures  of 
3T3-DI  cells were rinsed with  cold  PBS and  incubated 2 h at 4°C 
with  1.0 ml  per well of binding medium containing the concentra- 
tions of  PDGF  (a)  or  EGF  (b)  indicated on  the abscissa.  50 p.l of 
iodinated ligand was then added to give 0.2 ng/m112sI-PDGF (0) or 
0.25 ng/ml  ~2SI-EGF (O)  and  incubation  was continued  for 2 h  at 
4°C. Specific binding (means +  SEM of determinations on triplicate 
cultures) was measured as described in Materials and Methods, and 
is plotted as % of specific binding in binding medium alone. 
I00 
| 
14l 20 
=  ,  l  ,  ,  ,,11~1  i  i  i  i  ..... 
0  0.3  0.6  3X)  6~  I0 
PDGF  C~enfrgllc,  l, ng / ml 
IqGure  2  Effect  of PDGF and  EGF on '251-EGF binding to human 
fibroblasts  and  PDGF  receptor deficient  3T3  variants.  Confluent 
quiescent cultures of adult human foreskin fibroblasts (0) or of 3T3- 
PF2(f)  cells  (© were incubated for 2 h at 4°C  in  binding medium 
with the concentration of PDGF indicated on the abscissa), S0/~1 of 
~251-EGF was added to give 0.25 ng/ml I~51-EGF and the incubation 
was continued for  1 h.  Specific 12SI-EGF binding (mean +  SEM of 
determinations on triplicate cultures) was determined as described 
in  Materials and  Methods, and  is  plotted as % of  binding  in  the 
absence of PDGF. 
before measuring L25I-EGF binding. Binding of 12~I-EGF was 
still inhibited. However, PDGF dissociates so slowly from its 
receptor at 4°C (31) that most receptors occupied during the 
preincubation period would remain occupied during the incu- 
bation with E25I-EGF. To remove bound PDGF, we adapted 
the method of Haigler et al. (36) to remove cell surface-bound '25I-EGF. A 3-min incubation at 4°C with 0.1% acetic acid in 
150 mM NaCI with 0.1% BSA removed 89% of prebound  ]251- 
PDGF  and  78%  of prebound  '25I-EGF  (data  not  shown). 
Neither the 4°C preincubation nor the acetic acid rinse dam- 
aged  the cells or receptors as measured  by three  criteria  (a) 
<2% of the cells stained with the dye trypan blue, even after a 
4-h incubation at 4°C in binding medium followed by an acetic 
acid  rinse.  (b)  Binding of '25I-EGF and  ~25I-PDGF  to acid- 
treated cultures was  10t% and  103%, respectively, of binding 
to untreated  cultures.  (c)  Cultures  of 3T3 cells  incubated  in 
binding medium for 4 h at 4°C, then rinsed with acetic acid, 
were able to respond normally to subsequent addition of 5 ng/ 
ml EGF (3.7-fold stimulation in control, 3.2-fold stimulation 
in treated cultures) or PDGF (5.l-fold stimulation in control, 
4.4-fold stimulation  in  treated  cultures)  as  assayed  by [~H]- 
thymidine incorporation determined 20 h later. 
Table I shows that the acid rinse eliminated  the effects of 
preincubation with PDGF on subsequent  '2~I-PDGF binding, 
presumably by releasing prebound ligand, but did not signif- 
icantly lessen the inhibition of subsequent  v'~I-EGF binding. 
This demonstrates that PDGF is not acting by sterically block- 
ing ~25I-EGF binding and that the effect of PDGF is stable for 
at least the time needed to assay 125I-EGF binding. 
Kinetics of Inhibition 
At 4°C the effect of PDGF on '~SI-EGF binding is rapid but 
not immediate (Fig. 3). A portion of the time (about  10 min) 
needed  to  produce  a  50%  decrease  in  subsequent  ~25I-EGF 
binding probably reflects the time needed for binding of PDGF 
to its receptor (e.g., see reference 28 for binding kinetics under 
these  conditions).  However,  some  time  after  binding is  also 
required to develop the full effect, since the inhibition produced 
TABLE  I 
Effect of Preincubation with Mitogen on Subsequent Binding 
of l_abe[ed Mitogen 
1251-ligand binding % of 
control* 
Test substance dur-  Acetic acid 
ing preincubation  ~ZSl-ligand  PBS rinse  rinse 
0  100  100 
10 ng/ml  PDGF  17 +  4  101 +  4 
100 ng/ml  EGF  105 +__ 4  99 _+ 4 
200 ng/ml  FGF  ~2sI-PDGF  100 2:3  98 ±  5 
200 ng/ml  insulin  107 +_ 5  98 :t: 2 
100~l/ml  EDGF  83 +  3  93_+ 2 
0  100  100 
10 ng/ml  PDGF  18_  3  28--- 8 
100 ng/mt  EGF  38 -  2  128 +  13 
200 ng/ml  FGF  '2SI-EGF  67 +  2  78 +_+_ 6 
200 ng/ml  insulin  111 +  4  96 __+_  4 
100 #l/ml  EDGF  35 +  2  34 _+_ 2 
Confluent cultures of 3T3 cells were preincubated for 2 h at 4°C in binding 
medium  with  the indicated  test  substance.  ]-he  cultures were then rinsed 
three times  with  binding rinse and incubated for 3 rain  at 4°C with either 
PBS or 0.1% acetic  acid in 150 mM NaCl with 0.1% BSA. These rinse solutions 
were aspirated  and the cultures incubated for 30 rain  at 4°C with  I  ml per 
well of binding medium containing 0.2 ng/m112SI-PDGF  or 0.25 ng/m11251- 
EGF. 
* Specific  binding was  determined  as described  in  Materials  and  Methods, 
Specific  binding (means  _  SEM of determinations on triplicate cultures)  is 
expressed  as  %  of  the  value  obtained  after  preincubation  without  test 
addition. 
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FIGURE  3  Time  course  of 
effect  of  PDGF  on  sub- 
sequent  '251-EGF  binding. 
Confluent  quiescent  cul- 
tures  of  3T3  D1  cells  were 
rinsed  with  cold  PBS  and 
incubated  at  4°C  in  bind- 
ing medium  with  10 ng/ml 
PDGF.  After  the  times  in- 
dicated on the abscissa the 
cultures  were  rinsed  twice 
with PBS and incubated for 
3 rain at 4°C with either PBS (0) or 0.1% acetic acid in 150 mM NaCI 
with 0.5% BSA (O). These solutions  were aspirated and the cultures 
incubated  for  1 h  at 4°C  in  binding  medium  with  0.25  ng/ml  1251- 
EGF. Specific  binding  (mean  +  SEM of determinations  on triplicate 
cultures)  was  determined  as  described  in  Materials  and  Methods, 
and is plotted as % of the value obtained without exposure to PDGF. 
by short preincubation with PDGF is considerably less when 
the bound PDGF is removed with acetic acid before assaying 
~25I-EGF  binding,  than  when  the  PDGF  remains  bound 
throughout the assay period  (Fig.  3).  This  cannot be due to 
instability of the inhibition once established, since dissociation 
of bound PDGF has little effect after a preincubation of 2 h or 
more (Table I and Fig. 3). 
Specificity of Inhibition of EGF Binding 
Table I shows that PDGF is able to inhibit '251-EGF binding. 
The  inhibition  by  unlabeled  EGF  presumably  represents 
steric competition for EGF receptors, since it is eliminated by 
removing prebound EGF with acetic acid. Binding of ~25I-EGF 
is  also  inhibited  by  a  factor produced  by cultured  vascular 
endothelial cells in serum-free medium (Table I). Since endo- 
thelial  cell-derived  growth  factor (ECDGF)  does  not  block 
binding of '2~I-EGF to cells without PDGF receptors (unpub- 
lished  observations),  and  since  ECDGF  seems  to  bind  to 
PDGF receptors (28), it seems likely that the inhibition of ]25I- 
EGF binding by ECDGF is also mediated through the PDGF 
receptor. In three experiments, fibroblast growth factor (FGF) 
had  a  smaller,  though statistically  significant,  effect on  '2~I- 
EGF binding under these conditions (Table I). Although the 
preparation  of FGF  is  estimated  to be  only  10%  pure,  it  is 
unlikely  that  contamination  by  EGF  is  responsible  for the 
inhibition  of ]25I-EGF binding  since  the  inhibition  was  not 
reversed by acetic acid rinsing.  Significant contamination by 
PDGF is also unlikely since ]25I-PDGF binding is not signif- 
icantly reduced by 10 #g/ml FGF (28). High concentrations of 
insulin had no effect (Table I). The converse interaction, i.e., 
inhibition of ~25I-PDGF binding by preincubation with EGF, 
does not occur (Fig.  i b and Table I). 
To investigate the specificity of PDGF inhibition of ligand 
binding we investigated the sensitivity of ~2~I-insulin binding 
to inhibition by PDGF. Even extremely high concentrations of 
PDGF (400 ng/ml) did not reduce specific ~2~I-insulin binding 
to 3T3 cells (data not shown). 
Scatchard Analysis 
Fig. 4 a  shows that preincubation of 3T3 cell cultures with 
PDGF  at 4°C decreases  125I-EGF binding by increasing the 
apparent dissociation constant with little effect on the apparent 
number of EGF receptors, and that the magnitude of the effect 
depends  on  the  concentration  of PDGF  used.  A  simple  Kd 
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Scatchard  analysis  of  ~2SI-EGF binding.  (a)  Confluent 
quiescent cultures of 3T3-D1  were preincubated for 2 h  at 4°C in 
binding medium without PDGF  (O), with 0.5 mg/ml  PDGF  (O), or 
with 10 ng/ml PDGF  (ll).  Preincubation was terminated by rinsing 
with PBS and was followed by incubation for 2 h at 4°C in binding 
medium  with  concentrations  of  1251-EGF from  0.5  to  225  ng/ml. 
Specific t2SI-EGF binding (mean +  SEM of determinations on tripli- 
cate cultures) was determined as described in Materials and Meth- 
ods. (b) Cultures were preincubated for 2 h at 37°C in bicarbonate- 
buffered medium without PDGF  (0) or with  10 ng/ml  PDGF  ((3). 
Subsequent analysis was as described for (a). 
cannot be calculated for PDGF-preincubated cultures due to 
the pronounced curvature of the plot at low concentrations of 
EGF. However, from binding saturation plots we calculate that 
cultures preincubated  with  0,  0.5,  or  10 ng/ml PDGF show 
half-maximal 125I-EGF binding at 1.3, 1.6, and 2.0 nM, respec- 
tively, and express 40,200,  41,700,  and 43,800 EGF receptors/ 
cell, respectively. After pretreatment with either concentration 
of PDGF, the maximum ratio of bound to free 125I-EGF occurs 
when -12% of the EGF receptors are occupied. Fig 4b shows 
that preincubation of 3T3 cell cultures with  10 ng/ml PDGF 
at  37°C  for 2  h  causes a  similar,  though more pronounced, 
decrease  in  the  apparent  Kd  of ~2SI-EGF binding  with  no 
significant decrease in the apparent number of EGF receptors. 
DISCUSSION 
We have  found that  PDGF  can  reduce  the  binding  of low 
concentrations of ~25I-EGF by up to 80%, even when the cells 
are maintained at 4°C throughout the preincubation and mea- 
surement periods. This distinguishes PDGF from other inhib- 
itors of 125I-EGF binding that have been shown to require a 
period of incubation at 37°C to become effective (1, 3, 6, 7, 8, 
32, 34). We have demonstrated that inhibition does not result 
from direct competition by PDGF for 125I-EGF binding, nor 
from  a  general  inhibition  of specific  ligand  binding.  These 
fmdings suggest that caution must be used in interpreting the 
results of"competition" studies, including radioreceptor assays 
performed using living ceils, since there seems to be significant 
interaction between the two different receptor systems, even at 
4°C. 
We can only speculate  on the mechanism through which 
PDGF is affecting the EGF receptor. The process seems to be 
"catalytic" rather than stoichiometric in that occupation of the 
relatively  small  number  of PDGF  receptors  produces  half 
maximal  inhibition  of 12SI-EGF  binding.  Internalization  of 
EGF receptors in response to PDGF binding to its own receptor 
("cointernalization")  does  not  seem  to  be  involved,  since 
PDGF can inhibit 12~I-EGF binding even at 4°C and since the 
affmity,  but  not  the  number,  of EGF  receptors  is  reduced. 
Among the ligand-induced changes that are not prevented by 
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incubation at 4°C, two processes appear to be relatively good 
candidates for involvement in the interaction between the two 
receptor systems--stimulation of protein  kinase  activity and 
clustering of receptors. 
Although most energy-dependent reactions  are greatly re- 
duced at 4°C, the activity of the EGF- and PDGF-stimulated, 
tyrosine-specific protein kinases in membrane preparations is 
still substantial at 4°C (37, 38, 39, and our unpublished obser- 
vations). In each case, one of the substrates for the kinase seems 
to be the receptor for the activating ligand (39, 40). It is possible 
that binding of PDGF to its receptor stimulates phosphoryla- 
Lion of the  EGF  receptor  as  well  as  of its  own  receptor. 
Unfortunately, we have not yet been able to resolve phospho- 
rylated PDGF and EGF receptors on SDS polyacrylamide gels 
due to their very similar size (150,000-170,000 daltons) (39, 40, 
41, 42, 43). The effect of phosphorylation on the properties of 
the receptors is not known. However, phosphorylation-dephos- 
phorylation reactions have been shown to affect the enzymatic 
activities of several regulatory enzymes (reviewed in reference 
44). The effect ofphosphorylation on enzymes can be to change 
the Km for a substrate, the Ka for an activator, or the Ki for an 
inhibitor  (44).  If PDGF-stimulated  phosphorylation  of the 
EGF  receptor  were  involved  in  the  inhibition  of L~SI-EGF 
binding, the site(s)  of phosphorylation may be different from 
the site(s)  phospborylated in response to EGF binding, since 
removal  of EGF  (but  not  of PDGF)  restores  the  binding 
properties of the EGF receptor. Hunter and Cooper (45) and 
Gates and King (46) have reported that the EGF receptor can 
be phosphorylated at multiple sites. Possibly PDGF stimulates 
phosphorylation of a very stable site. 
Another candidate for involvement in the PDGF inhibition 
of EGF binding is an induced aggregation of EGF receptors 
with PDGF receptors. Some receptors seem to be present in 
small patches even before ligand addition.  Low density lipo- 
protein (LDL) receptors are largely preconcentrated in coated 
pit  regions  (47).  Large-scale patching and  internalization  of 
receptors  does  not  occur at  4°C  (33,  34,  36).  Nevertheless, 
several receptors have been shown to be mobile in the plasma 
membrane  to 4°C  (48,  49)  and  to form small  aggregates in 
response to ligand binding (48). It is possible that the inclusion 
of an EGF receptor in the same aggregate as PDGF receptors 
could influence its ability to bind 12~I-EGF. Certainly, receptors 
are  sensitive  to general  changes  in  their  local environment. 
Phospholipase C and other lipid-interactive substances seem to 
decrease the affinity of 125I-EGF binding to mink lung ceils 
(4), and removal of the EGF receptor from the membrane into 
Triton micelles reduces its  affinity for EGF by  10-fold (50). 
Changes in other membrane proteins associated with receptors 
have also been implicated in changes in receptor properties. 
Maturo and Hollenberg (51) reported a membrane glycoprotein 
whose association with the solubilized, partially purified insulin 
receptor altered its apparent affinity for 125I-insulin. 
It is intriguing to speculate on the possible significance of 
this phenomenon for cell behavior. Dicker and Rozengurt (52) 
reported that phorbol acetate and EGF had synergistic effects 
in  stimulating  DNA synthesis,  despite  the  fact that  phorbol 
acetate reduces 12~I-EGF binding.  Wolfe et al.,  (53)  reported 
that  EGF  does not down-regulate its  own receptor if HeLa 
ceils  are cultured in defined medium without serum.  PDGF 
may represent the component in serum which is necessary for 
the down-regulation of the EGF receptor in this system. It is 
thus possible that the inhibition of 12SI-EGF binding by PDGF 
that we have described in this report is only one manifestation 
of the interaction between the PDGF and EGF receptors, i.e., PDGF may also alter the ability of the EGF receptors to affect 
intracellular events or to be internalized and degraded. In any 
case, the ability of one growth factor to alter the properties of 
receptors for a  second growth factor adds another locus to the 
sites at which the different polypeptide hormones could interact 
to potentiate or inhibit their physiological effects. 
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Note Added in Proof." We have recently reevaluated the PDGF content 
of our  purified  PDGF  using determinations of protein content by 
OD28o, Lowry assay, and quantification of silver-stained SDS PAGE; 
and using determinations of purity by silver-stained SDS PAGE and 
determination of the fraction of t251-PDGF able to bind specifically to 
PDGF-responsive cells. On the basis of this new information we have 
concluded that the values for PDGF concentrations reported in this 
paper should be multiplied by 0.28 to obtain the corrected values. 
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